Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces 'first patient' randomised in EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in NASH

Posted On: 2021-10-22 17:48:11 (Time Zone: IST)


Zydus, a leading discovery based, global pharmaceutical company today announced that it has randomised the First patient into the Phase 2(b) Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled clinical trial to evaluate Efficacy and Safety of Saroglitazar Magnesium in subjects with Non-Alcoholic Steatohepatitis and Fibrosis. Zydus had earlier received permission from the USFDA [ClinicalTrials.gov Identifier: NCT05011305].

The EVIDENCES-X™ liver biopsy driven Phase 2(b) trial will be led by Prof. Naga Chalasani, M.D., Interim Chair, Department of Medicine, Indiana University School of Medicine and Prof. Arun J. Sanyal, M.D., Division of Gastroenterology, Virginia Commonwealth University as co-Principal Investigators. The EVIDENCES-X™ trial will randomise 240 subjects in a 1:1:1 ratio to Saroglitazar 2 mg, Saroglitazar 4 mg or Placebo and study the primary endpoint "Resolution of steatohepatitis with no worsening of fibrosis" over a period of 76 weeks. The secondary end-points will include improvement in liver fibrosis with no increase in NAS for ballooning, inflammation or steatosis, 2 points improvement in NAS, Improvement in steatosis, ballooning, inflammation and fibrosis from liver biopsy, Histological score changes in steatosis, ballooning, inflammation and fibrosis.

Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders. Experts estimate that about 25% of adults have NAFLD worldwide (K Nonalcoholic steatohepatitis: global impact and clinical consequences, Younossi et al., Endocr Connect. 2021 Oct 7;10(10):R240-R247. doi: 10.1530/EC-21-0048.). NASH is a progressive form of NAFLD and is characterised by histologic evidence of hepatic steatosis, lobular inflammation, hepatocyte ballooning with or without pericellular fibrosis, and/or MalloryDenk bodies, which can progress to liver cirrhosis, liver cancer and need for liver transplant or death. Experts estimate about 5 - 20 % of adults worldwide have NASH placing significant clinical, economical, and health-related quality of life (HRQoL) burden for treating this liver disease (Source: Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. Jamie O-Hare et. al., JHEP Reports 2020 vol. 2 j 100142). Analysts estimate the global market for Non-alcoholic steatohepatitis (NASH) treatment will reach $27 billion in 2029 (Source: Globaldata).

Speaking on the new development, Chairman of Cadila Healthcare Ltd., Mr. Pankaj R. Patel said, "As there is currently no drug approved for the treatment of NASH in the USA, this life threatening liver disease is a high unmet medical need. We are committed to develop novel therapeutics for patients living with liver diseases and fibrosis. We stand encouraged that the findings from the earlier EVIDENCES-IV Phase 2 clinical study have been published as original article by Samer et al along with the editorial by Prof. Sven Francque, M.A. a leading hepatologist from Belgium in the October edition of Hepatology, the Journal of American Association for the Study of Liver Diseases (AASLD)".

NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver, which can progress to liver cirrhosis, need for liver transplant or death. Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA). The USFDA has granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC. The European Medicines Agency (EMA) has designated "Saroglitazar magnesium" with Orphan status for Treatment of Primary Biliary Cholangitis.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 502.40 as compared to the previous close of Rs. 510.20. The total number of shares traded during the day was 80723 in over 1943 trades.

The stock hit an intraday high of Rs. 517.70 and intraday low of 501.00. The net turnover during the day was Rs. 41003473.00.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

BHEL wins CII-Exim Bank Platinum Awards for Business Excellence

V-Mart Retail Ltd opens one new store in Haryana

Vidli Restaurants Limited board approves rights issue at Rs. 10

Innovators Facade Systems Limited receives order from DLF Group

Infosys collaborates with One of Europe's Greenest Data Centers to accelerate Daimler's transition to Sustainable Mobility

Dharamsi Morarji Chemical Company Ltd to list in NSE from Dec 1, 2021

Fitch affirms Axis Bank at 'BB+', Outlook Negative

TCS helps AGL embrace New AI-powered Operating Model to transform Customer Experience

Dhruv Consultancy Services Limited receives LOA for project worth Rs. 5.04 crore

Arvind Ltd update on Ankur unit

Lupin launches Sciflix a mobile-friendly learning platform for post graduate students specializing in pulmonology

ICRA-assigned Credit Rating for 100.00 crore bank lines of Rane Holdings Limited

ITI Limited installs 100 KW Captive Rooftop Solar Power Plant in Lucknow, Uttar Pradesh

GIC to invest in IRB Infrastructure Developers Limited

Vishvprabha Ventures Ltd Fixes Record Date for Rights Issue of equity shares

Earum Pharmaceuticals Ltd fixes Record Date for Stock Split

ICRA upgrades credit rating of DLF Limited to [ICRA] AA- with Stable outlook

IIFL Home Finance Ltd disbursed loans over Rs. 2500crore, as on 30 September, 2021

Kotak Mahindra Bank reaches One Million FASTags Milestone

Accor renews partnership with IndiGo's 6E Rewards program to offer accelerated travel and stay benefits

Rossari Biotech Ltd. appoints Ketan Sablok as the Group Chief Financial Officer

Vedanta's Sesa Goa Iron Ore Business pledges to become carbon neutral by 2050

CL Educate liquidates third land parcel this year

Reliance Capital Ltd welcomes RBI move to resolve company's debt through IBC

Knowledge Marine & Engineering Works Ltd receives LoA from Vizag Port Trust for patrol boat

Patel Integrated Logistics Ltd board to consider rights shares allotment on Dec 2, 2021

Tatva Chintan Pharma Chem Ltd acquires land at Dahej-III GIDC Estate, Bharuch

Intec Capital Ltd accepts OTS proposal from The Bank of Maharashtra

Sayaji Hotels Ltd arm signs 8 new properties

Coal India Ltd board declares interim dividend of Rs. 9

BSL Ltd updates on credit rating

Ratnamani Metals & Tubes Ltd receives new Domestic Orders of Rs.297.87 Crores

TCS Named a Leader in IDC MarketScape for Worldwide Managed Multicloud Services

James Warren Tea Limited board approves buyback at Rs. 295 through tender offer

Goeld frozen Foods starts operations in Bhopal

Happiest Minds wins Platinum and Gold Awards for its 2021 Annual Report from LACP

Reliance Industries Ltd denies bid for BT

TTK Prestige Ltd fixes Dec 15, 2021 as record date for stock split

National Fittings Ltd announces redemption of preference shares

LIC gets RBI nod for increasing stake in Kotak Mahindra Bank to 9.99%

Brooks Steriscience Ltd gets marketing authorizaiton in Germany for Meropenem

CRISIL reaffirms rating of Ruchira Papers Ltd

Man Industries India Ltd receives news orders of Rs. 325 crores

Indian Sucrose Ltd starts sugar crushing for season 2021-22

Capri Global Capital Limited partners with State Bank of India for Co-Lending to MSMEs

Genesys International Corporation Limited to launch India 3D Maps Program

Asian Paints Ltd inks MoU for expansion project at an outlay of Rs. 960 crores

Shakti Pumps India Limited to form subsidiary for business in EV Motor

IndusInd Bank Ltd updates on resignations at Bharat Financial Inclusion Ltd

MICL Group to jointly develop Luxurious Residential Project at Tardeo, Mumbai


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020